The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...

KIIT-DU ( has secured an impressive 4th position in India in the inaugural Times Higher Education (THE) Interdisciplinary Science Rankings 2025, which recognizes universities excelling in ...

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival ...

Report on how AI is driving market transformation - The global microbiomes market size is estimated to grow by USD 1.13 ...

Schlafender Hase announced today the release of TVT 12, the latest version of its industry-trusted proofreading software. This upgrade features enhanced tools for efficiency and regulatory compliance, ...

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem ...

This trend is a direct reflection of the continued demand from the medical community for MaaT Pharma’s drug candidate MaaT013. Nomination of Eric Soyer as Chief Financial Officer and transition of ...

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem ...

MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access programme (EAP).

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Reply to: Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide-Based Mismatched Unrelated Donor Transplantation Data were pooled from six CheckMate studies in ICI ...